Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,632 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study.
Fukuhara N, Maruyama D, Hatake K, Nagai H, Makita S, Kamezaki K, Uchida T, Kusumoto S, Kuroda J, Iriyama C, Yanada M, Tsukamoto N, Suehiro Y, Minami H, Garcia-Vargas J, Childs BH, Yasuda M, Masuda S, Tsujino T, Terao Y, Tobinai K. Fukuhara N, et al. Among authors: nagai h. Int J Hematol. 2023 Jan;117(1):100-109. doi: 10.1007/s12185-022-03455-0. Epub 2022 Sep 29. Int J Hematol. 2023. PMID: 36175779 Free PMC article. Clinical Trial.
Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, Ishizawa K, Yamamoto J, Watanabe T, Uike N, Choi I, Terui Y, Usuki K, Nagai H, Uoshima N, Tobinai K; Japanese Bendamustine Lymphoma Study Group. Ohmachi K, et al. Among authors: nagai h. Cancer Sci. 2010 Sep;101(9):2059-64. doi: 10.1111/j.1349-7006.2010.01635.x. Cancer Sci. 2010. PMID: 20626754 Free PMC article. Clinical Trial.
Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H, Ogura M, Kusumoto S, Takahashi N, Yamaguchi M, Takayama N, Kinoshita T, Motoji T, Ohyashiki K, Kosugi H, Matsuda S, Ohnishi K, Omachi K, Hotta T. Nagai H, et al. Eur J Haematol. 2011 Feb;86(2):117-23. doi: 10.1111/j.1600-0609.2010.01552.x. Epub 2010 Dec 29. Eur J Haematol. 2011. PMID: 21070370 Clinical Trial.
Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
Tobinai K, Igarashi T, Itoh K, Kurosawa M, Nagai H, Hiraoka A, Kinoshita T, Uike N, Ogura M, Nawano S, Mori S, Ohashi Y; IDEC-C2B8 Study Group. Tobinai K, et al. Among authors: nagai h. Cancer Sci. 2011 Sep;102(9):1698-705. doi: 10.1111/j.1349-7006.2011.02001.x. Epub 2011 Jul 8. Cancer Sci. 2011. PMID: 21645173 Free article. Clinical Trial.
Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups.
Kihara R, Watanabe T, Yano T, Uike N, Okamura S, Kawano F, Hanada S, Sunami K, Inoue N, Sawamura M, Yoshida S, Shimomura T, Kitano K, Kojima Y, Horibe K, Nagai H. Kihara R, et al. Among authors: nagai h. Int J Hematol. 2013 Jan;97(1):98-102. doi: 10.1007/s12185-012-1243-2. Epub 2012 Dec 15. Int J Hematol. 2013. PMID: 23243003
2,632 results